Matthew A. J. Duncton

2.3k total citations · 1 hit paper
49 papers, 1.8k citations indexed

About

Matthew A. J. Duncton is a scholar working on Organic Chemistry, Molecular Biology and Sensory Systems. According to data from OpenAlex, Matthew A. J. Duncton has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Organic Chemistry, 25 papers in Molecular Biology and 7 papers in Sensory Systems. Recurrent topics in Matthew A. J. Duncton's work include Chemical Synthesis and Analysis (8 papers), Synthesis and Biological Evaluation (7 papers) and Ion Channels and Receptors (7 papers). Matthew A. J. Duncton is often cited by papers focused on Chemical Synthesis and Analysis (8 papers), Synthesis and Biological Evaluation (7 papers) and Ion Channels and Receptors (7 papers). Matthew A. J. Duncton collaborates with scholars based in United States, United Kingdom and Belgium. Matthew A. J. Duncton's co-authors include Fabien Vincent, Gerald Pattenden, Michael Kelly, Daniel Emerling, Jeff DeFalco, Amy Gustafson, Rajinder Singh, Donogh J. R. O’Mahony, Michelle Dourado and Margaret Nguyen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Matthew A. J. Duncton

47 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Minisci reactions: Versatile CH-functionalizations for medicinal chemists

2011 521 citations Matthew A. J. Duncton profile →

Peers

Countries citing papers authored by Matthew A. J. Duncton

Since Specialization

Citations

This map shows the geographic impact of Matthew A. J. Duncton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. J. Duncton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. J. Duncton more than expected).

Fields of papers citing papers by Matthew A. J. Duncton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. J. Duncton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. J. Duncton. The network helps show where Matthew A. J. Duncton may publish in the future.

Co-authorship network of co-authors of Matthew A. J. Duncton

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. J. Duncton. A scholar is included among the top collaborators of Matthew A. J. Duncton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. J. Duncton. Matthew A. J. Duncton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 4193: Novel APE1 endonuclease inhibitors as precision oncology therapeutics in high grade serous ovarian cancers discovered and developed from crystallography-based fragment library screening 2025 ·Cancer Research ·Debanu Das, Ashley M. Deacon, Matthew A. J. Duncton, (unknown), (unknown), (unknown), Emad A. Rakha, (unknown), Madhusudhan Srinivasan	0
2	A New Drug Discovery Platform: Application to DNA Polymerase Eta and Apurinic/Apyrimidinic Endonuclease 1 2023 ·International Journal of Molecular Sciences ·Debanu Das, Matthew A. J. Duncton, Taxiarchis M. Georgiadis, Patricia Pellicena, Jennifer Clark, Robert W. Sobol, Millie M. Georgiadis, John King-Underwood, David V. Jobes, (unknown), Yang Gao, Ashley M. Deacon, David M. Wilson	6
3	Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma 2023 ·Science Translational Medicine ·Kavita Y. Sarin, (unknown), Brittney Sell, (unknown), Matthew A. J. Duncton, (unknown), Wenchao Sun, (unknown), (unknown), Carlos Moran Segura, Jonathan V. Nguyen, Roderick T. Bronson, Scott R. Plotkin, Gerd G. Kochendoerfer, (unknown), (unknown), Christopher Powala, Mark P. de Souza, Kenneth Y. Tsai	3
4	Tuning the Reactivity of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Optimal in Vivo Efficacy 2023 ·ACS Medicinal Chemistry Letters ·Vadim Markovtsov, Matthew A. J. Duncton, (unknown), Sothy Yi, Sylvia Braselmann, (unknown), (unknown), Jiaxin Yu, Alexander M. Owyang, (unknown), (unknown), Gary Park, Esteban S. Masuda, Simon J. Shaw	2
5	Early Drug Discovery and Development of Novel Cancer Therapeutics Targeting DNA Polymerase Eta (POLH) 2021 ·Frontiers in Oncology ·David M. Wilson, Matthew A. J. Duncton, (unknown), (unknown), Taxiarchis M. Georgiadis, Patricia Pellicena, Ashley M. Deacon, Yang Gao, Debanu Das	10
6	Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response 2020 ·Progress in Biophysics and Molecular Biology ·David M. Wilson, Ashley M. Deacon, Matthew A. J. Duncton, Patricia Pellicena, Millie M. Georgiadis, Andrew Yeh, A.S. Arvai, Davide Moiani, John A. Tainer, Debanu Das	24
7	LB949 Development of topical MEK inhibitor, NFX-179, as a chemopreventive agent for squamous cell carcinoma 2020 ·Journal of Investigative Dermatology ·Aatman Shah, Brittney Sell, Wenchao Sun, Matthew A. J. Duncton, (unknown), John Kincaid, Kavita Y. Sarin, Kenneth Y. Tsai	1
8	Identification of orally-bioavailable antagonists of the TRPV4 ion-channel 2015 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Margaret Nguyen, Donogh J. R. O’Mahony, (unknown), (unknown), Qingling Zhang, Luna Liu, Michelle Dourado, (unknown), Victor Yip, Jeff DeFalco, Amy Gustafson, Daniel Emerling, Michael Kelly, John Kincaid, Fabien Vincent, Matthew A. J. Duncton	29
9	A concise one-pot synthesis of trifluoromethyl-containing 2,6-disubstituted 5,6,7,8-tetrahydroquinolines and 5,6,7,8-tetrahydronaphthyridines 2013 ·Organic & Biomolecular Chemistry ·Russell J. Johnson, Donogh J. R. O’Mahony, (unknown), Matthew A. J. Duncton	12
10	TRPV4 Agonists and Antagonists 2011 ·Current Topics in Medicinal Chemistry ·Fabien Vincent, Matthew A. J. Duncton	118
11	5-Benzyloxytryptamine as an antagonist of TRPM8 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jeff DeFalco, (unknown), Michelle Dourado, Daniel Emerling, Matthew A. J. Duncton	24
12	Preparation of Heteroaryloxetanes and Heteroarylazetidines by Use of a Minisci Reaction 2009 ·The Journal of Organic Chemistry ·Matthew A. J. Duncton, M. Angels Estiarte, Russell J. Johnson, Matthew Cox, Donogh J. R. O’Mahony, (unknown), Michael Kelly	82
13	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): Identification of phenmedipham and amperozide as FAAH inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Fabien Vincent, Margaret Nguyen, Daniel Emerling, Michael Kelly, Matthew A. J. Duncton	8
14	Dibutyl 2-(trifluoromethyl)cyclopropylboronate as a useful (trifluoromethyl)cyclopropyl donor: application to antagonists of TRPV1 2009 ·Tetrahedron Letters ·Matthew A. J. Duncton, (unknown), (unknown), J. Satyanarayana, (unknown), (unknown), (unknown), John Kincaid, Michael Kelly	31
15	Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor 2009 ·Bioorganic & Medicinal Chemistry Letters ·Jeff DeFalco, (unknown), Amy Gustafson, Daniel Emerling, Michael Kelly, Matthew A. J. Duncton	50
16	Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2 2008 ·Bioorganic & Medicinal Chemistry ·Matthew A. J. Duncton, Eugene L. Piatnitski Chekler, (unknown), (unknown), Wai C. Wong, Leon M. Smith, Joel K. Kawakami, Alexander S. Kiselyov, Daniel L. Milligan, (unknown), Yaron R. Hadari, Ying Wang, Sheetal Patel, (unknown), James R. Tonra, David Surguladze, (unknown), Paul Kussie, Peter Böhlen, Jacqueline Doody	34
17	Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase 2006 ·Bioorganic & Medicinal Chemistry Letters ·Leon M. Smith, Wai C. Wong, Alexander S. Kiselyov, (unknown), (unknown), Yong‐Jiang Xu, Matthew A. J. Duncton, Ki Hyun Kim, Evgueni L. Piatnitski, Jacqueline Doody, Ying Wang, (unknown), Daniel L. Milligan, John Columbus, (unknown), (unknown), (unknown), Yaron R. Hadari	25
18	Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase 2005 ·Bioorganic & Medicinal Chemistry Letters ·Evgueni L. Piatnitski, Matthew A. J. Duncton, Alexander S. Kiselyov, (unknown), (unknown), Daniel L. Milligan, (unknown), Wai C. Wong, Joel K. Kawakami, Jacqueline Doody	44
19	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II 2005 ·Bioorganic & Medicinal Chemistry Letters ·Matthew A. J. Duncton, Evgueni L. Piatnitski, (unknown), Leon M. Smith, Alexander S. Kiselyov, Daniel L. Milligan, (unknown), Wai C. Wong, Joel K. Kawakami, Jacqueline Doody	30
20	4-Substituted-3-phenylquinolin-2(1H)-ones: Acidic and Nonacidic Glycine SiteN-Methyl-d-aspartate Antagonists withinVivoActivity 1997 ·Journal of Medicinal Chemistry ·Robert W. Carling, Paul D. Leeson, Kevin W. Moore, Christopher R. Moyes, Matthew A. J. Duncton, Martin L. Hudson, Raymond Baker, Alan C. Foster, Sarah Grimwood, John A. Kemp, George Marshall, Mark D. Tricklebank, Kay L. Saywell	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact